CN110624011A - Preparation and application of coke hawthorn carbon quantum dots (nano particles/nano particles) - Google Patents
Preparation and application of coke hawthorn carbon quantum dots (nano particles/nano particles) Download PDFInfo
- Publication number
- CN110624011A CN110624011A CN201810658397.1A CN201810658397A CN110624011A CN 110624011 A CN110624011 A CN 110624011A CN 201810658397 A CN201810658397 A CN 201810658397A CN 110624011 A CN110624011 A CN 110624011A
- Authority
- CN
- China
- Prior art keywords
- hemorrhage
- pain
- quantum dots
- nano particles
- carbon quantum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000009917 Crataegus X brevipes Nutrition 0.000 title claims abstract description 28
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 title claims abstract description 28
- 235000009685 Crataegus X maligna Nutrition 0.000 title claims abstract description 28
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 title claims abstract description 28
- 235000009486 Crataegus bullatus Nutrition 0.000 title claims abstract description 28
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 title claims abstract description 28
- 235000009682 Crataegus limnophila Nutrition 0.000 title claims abstract description 28
- 235000004423 Crataegus monogyna Nutrition 0.000 title claims abstract description 28
- 235000002313 Crataegus paludosa Nutrition 0.000 title claims abstract description 28
- 235000009840 Crataegus x incaedua Nutrition 0.000 title claims abstract description 28
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000002105 nanoparticle Substances 0.000 title abstract description 8
- 240000000171 Crataegus monogyna Species 0.000 title abstract 2
- 239000000571 coke Substances 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000002096 quantum dot Substances 0.000 claims abstract description 8
- 238000000502 dialysis Methods 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 208000002193 Pain Diseases 0.000 claims abstract 6
- 230000036407 pain Effects 0.000 claims abstract 6
- 239000002245 particle Substances 0.000 claims abstract 4
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract 3
- 206010037660 Pyrexia Diseases 0.000 claims abstract 3
- 230000007815 allergy Effects 0.000 claims abstract 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract 3
- 238000002347 injection Methods 0.000 claims abstract 3
- 239000007924 injection Substances 0.000 claims abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 3
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 208000026935 allergic disease Diseases 0.000 claims abstract 2
- 230000005540 biological transmission Effects 0.000 claims abstract 2
- 230000000740 bleeding effect Effects 0.000 claims abstract 2
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 241001092040 Crataegus Species 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 13
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 238000000197 pyrolysis Methods 0.000 claims 2
- 206010000087 Abdominal pain upper Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 1
- 206010014020 Ear pain Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 206010017788 Gastric haemorrhage Diseases 0.000 claims 1
- 206010019705 Hepatic pain Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 206010027514 Metrorrhagia Diseases 0.000 claims 1
- 206010028024 Mouth haemorrhage Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000009613 Oral Hemorrhage Diseases 0.000 claims 1
- 206010031009 Oral pain Diseases 0.000 claims 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims 1
- 208000037486 Postoperative Hemorrhage Diseases 0.000 claims 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 206010038063 Rectal haemorrhage Diseases 0.000 claims 1
- 206010038460 Renal haemorrhage Diseases 0.000 claims 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 claims 1
- 206010051496 Rhinalgia Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039897 Sedation Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041647 Splenic haemorrhage Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010053615 Thermal burn Diseases 0.000 claims 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 230000002052 anaphylactic effect Effects 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 201000005311 drug allergy Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- 208000021760 high fever Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000003208 petroleum Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 230000036280 sedation Effects 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 208000005392 Spasm Diseases 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 230000001914 calming effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 3
- 102400000472 Sucrase Human genes 0.000 description 3
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 3
- 102000016679 alpha-Glucosidases Human genes 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 235000011073 invertase Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 108010001394 Disaccharidases Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000000026 X-ray photoelectron spectrum Methods 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a method for extracting, separating and purifying quantum dots (nano particles/nano particles) from scorched hawthorn, which comprises the following steps: extracting fructus crataegi with solvent, dialyzing with dialysis bag with molecular weight greater than 1000Da, or ultrafiltering to obtain fructus crataegi preparata carbon quantum dots which exhibit blue fluorescence under ultraviolet lamp 365nm and have particle diameter less than 100nm measured by transmission electron microscope and mainly comprise C, H, O and N; the invention also relates to the application of the quantum dot in the field of medicine, and the quantum dot is used for reducing blood sugar, stopping bleeding, easing pain, calming, resisting inflammation, resisting allergy, resisting oxidation, relieving fever, relieving spasm, reducing blood sugar, reducing blood pressure, resisting side reaction of tumor chemotherapy drugs and the like after being administrated by injection, oral administration or external application and other ways.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to preparation of coke hawthorn carbon quantum dots and application of the coke hawthorn carbon quantum dots in the field of medicines.
Background
Haw, originally recorded in Xin Xiu Ben Cao of Tang, is a traditional food-digesting medicine with a history of more than a thousand years of use, and its processing method is recorded in the classic medical record of the past generation and has abundant resources.
The method for moxibustion of hawthorn mainly comprises stir-frying (stir-frying to yellow), stir-frying to brown, carbonizing, stir-frying with auxiliary materials, steaming and the like. The stir-frying method is originally found in the Ming Dynasty 'Danxi Xin Fa' (Hawthorn fruit: stir-frying, its posterity (compendium of medicine), Qing Dynasty (Collection of entagles) and Wen Bing (treatise on epidemic febrile diseases) are recorded with stir-fried haw or haw pulp. In Yunnan materia Medica, there are "Hawthorn seeds: the record of stir-frying yellow is recorded in the book of treatise on doctor Zong and the book of dialectical warm diseases in the Qing Dynasty, while the record of stir-frying black in the book of Ming Dynasty, the record of stir-frying black in powder and stir-frying black in powder can treat blood stasis (the book of treatise on doctor Zong) mainly aims at changing the property of medicine and facilitating the dispensing. The records of charred Haw fruit appear in the documents of the Qing Dynasty, Wuwei Tong medical records and so on. The steaming method is originally found in the Ministry of the Heart of Danxi (Danxi Heart method) and hawthorn: steaming and drying in the sun. From the Ming Dynasty, there are four kinds of auxiliary materials and five kinds of preparation methods in the past literature of hawthorn processing with auxiliary materials. Ming Dynasty, the regulation and treatment standard rope, is recorded with vinegar-fried. The Qing Dynasty, the Yi Zong jin Jian, is fried with wine, the Wen Shi Yi, is fried with ginger juice, and the Qing Dynasty, the Ben Jing Jie Yuan, is soaked with urine and enucleation. Modern processed products of hawthorn mainly comprise: cleaning fructus crataegi, parched fructus crataegi, and fructus crataegi preparata. At present, the research make internal disorder or usurp on stir-frying is mainly focused on the change of chemical components, but no clear answer is provided for the material basis and principle of the pharmacodynamic action of stir-frying.
Disclosure of Invention
The invention extracts and separates carbon quantum dots (nano particles/nano particles) from the scorched hawthorn for the first time, and discovers that the scorched hawthorn carbon quantum dots have strong biological effects of inhibiting intestinal canal disaccharidase and inhibiting sucrase and maltase in vitro for the first time.
The technical scheme is as follows: the invention provides a method for extracting and separating carbon quantum dots from scorched hawthorn fruits. The invention also provides the biological activity of the charred hawthorn carbon quantum dots and the application thereof in the field of medicine.
The preparation method specifically comprises the following steps: the charred hawthorn is prepared by a baking method, carbon quantum dots are extracted from the charred hawthorn by using a solvent, and the high-purity carbon quantum dots are obtained by further separation and purification including dialysis, ultrafiltration, chromatography and other technical methods.
Drawings
FIG. 1 is a diagram of UV, fluorescence, X-ray diffraction and infrared spectrums of coke hawthorn carbon quantum dots
FIG. 2 is an X-ray photoelectron spectrum of coke hawthorn carbon quantum dots
Detailed Description
Example 1: preparation of coke hawthorn carbon quantum dots
Putting the hawthorn medicinal material decoction pieces into a crucible, covering, putting into a muffle furnace, heating to 260 ℃, keeping the constant temperature for 1h, naturally cooling to room temperature, opening the muffle furnace, and taking out to obtain the scorched hawthorn.
Extracting fructus crataegi with pure water for 3 times, mixing water solutions, concentrating, and dialyzing with 1KD dialysis bag to obtain high-purity fructus crataegi carbon quantum dot solution.
Example 2: preparation of coke hawthorn carbon quantum dots
Putting fructus crataegi medicinal material decoction pieces into a crucible, placing into the crucible, covering, placing into a muffle furnace, heating to 350 deg.C, maintaining constant temperature for 1 hr, naturally cooling to room temperature, opening the muffle furnace, taking out, and sucking out black liquid to obtain fructus crataegi preparata. Extracting fructus crataegi with pure water for 3 times, mixing water solutions, concentrating, and ultrafiltering with 10KD ultrafiltering tube to obtain filtrate as high-purity fructus crataegi carbon quantum dot solution.
Example 3 inhibition of disaccharidase activity by charred hawthorn carbon quantum dots:
1. mice were fasted for 12 hours the night before the experiment and were fed normally.
2. The mice are killed by removing the neck, the skin of the abdomen is cut along the midline of the abdomen, the small intestine is selected and cut off, the intestines with the two ends of 1cm are discarded, and the small intestine in the middle section is taken. The intestinal contents are squeezed out, rinsed with normal saline, sucked dry and weighed. After adding cold normal saline (1: 10, W/V) to the small intestine sample, homogenizing with a homogenizer, and refrigerating for use.
3. Determination of maltase and sucrase activity: dividing an experimental sample into a control group and an experimental group (a group with high carbon quantum dot and medium and low concentration), taking 0.1ml of homogenate liquid from the experimental group, adding carbon quantum dot of charred triplet (high, medium and low concentration), then adding 0.1ml of 0.056mol/L substrate (maltose and sucrose), accurately reacting for 30min in a water bath at 37 ℃, immediately putting into a boiling water bath to terminate the reaction, and measuring the concentration of glucose in the solution by using blood glucose test paper and a glucometer. In the control group, 0.1ml of homogenate without carbon quantum dots was taken, and the post-operation method was the same as that of the experimental group.
Definition of enzyme activity unit: decomposing 1.0 mu mol/L substrate per gram of mucosa per minute to obtain a unit U of enzyme activity. Disaccharide Activity (U/g) ═ xn/30a
Wherein x is glucose released by the reaction (mu mol/L); a is disaccharide glucose release amount, maltose is 2, and sucrose is 1; n is the sample dilution factor; and 30 is reaction time (min).
And calculating the enzyme activity and the inhibition rate of the carbon quantum dots on the enzyme activity after adding charred hawthorn fruit carbon quantum dots by taking the enzyme activity of the charred hawthorn fruit carbon quantum dots as 100%. The inhibition rate is (1-enzymatic activity after charred triplet carbon quantum dot) 100%
Statistical analysis
All experimental data were processed using SPSS software and tested for significance of differences using One-way ANOVA (LSD), and the data are expressed as "mean ± standard deviation".
TABLE 1 Experimental results of the inhibiting activity of sucrase by charred triplet carbon quantum dots
| Group of | Relative enzyme activity (%) | P value | Inhibition ratio (%) |
| H | 62.7±13 | 0.000 | 37.3 |
| M | 41.1±17 | 0.000 | 58.8 |
| L | 85.0±9 | 0.085 | 15.0 |
| PBS | 100.0±18 |
Note: p < 0.05 compared to control; p < 0.01.
TABLE 2 Activities of Malassezia charra quantum dots for inhibiting maltase
| Group of | Relative enzyme activity (%) | P value | Inhibition ratio (%) |
| H | 43.7±11.8 | 0.598 | 28.1 |
| M | 98.1±2.8 | 0.599 | 1.0 |
| L | 94.3±2.5 | 0.134 | 2.8 |
| PBS | 100.0±1.3 |
Claims (7)
1. A method for extracting and purifying quantum dots from fructus crataegi preparata is provided.
The preparation method of the parched fructus crataegi comprises parching, microwave heating, and decocting. Extracting with solvent, dialyzing with dialysis bag with molecular weight of 1-10 KDa, and collecting the fraction retained in the dialysis bag, or ultrafiltering with ultrafiltration tube of 10KD to obtain filtrate. The carbon quantum dots are characterized in that: blue fluorescence under an ultraviolet lamp of 365nm, and a transmission electron microscope for measuring the particle size of 1-100nm, wherein the particle size mainly comprises C, O, N element and a small amount of sulfur element.
2. Application of fructus crataegi preparata quantum dots in the field of medicine is provided.
Including but not limited to hemostasis, analgesia, sedation, anti-inflammation, anti-allergy, anti-oxidation, antipyretic, spasmolysis, hypoglycemic, antihypertensive, anti-side effects of tumor chemotherapy drugs.
3. The method for preparing scorched hawthorn fruit according to claim 1, wherein the temperature of the dry distillation method is 100-1500 ℃. The extraction solvent is one or more of water, methanol, ethanol, ethyl acetate, ethyl formate, methyl acetate, acetone, diethyl ether, chloroform, and petroleum ether.
4. The method for preparing scorched hawthorn fruit according to claim 3, wherein the temperature of the dry distillation method is 200-500 ℃.
5. The quantum dot of claim 1 having a particle size of 1-20 nm. The elemental composition of quantum dots includes, but is not limited to C, H, O, N and the S element.
6. The use of claim 2, wherein the dosage form is injection, powder for injection, oral liquid, hard capsule, soft capsule, tablet, suppository, water-paste pill, honeyed pill, concentrated pill, ointment, powder, emulsion, paste, and liniment.
7. The use according to claim 2 for the treatment or prevention of a condition which is: dyspepsia, anorexia, etc.; diabetes, hyperglycemia; various bleeding diseases, blood vessel burst, cerebral hemorrhage, liver hemorrhage, pulmonary hemorrhage, renal hemorrhage, splenic hemorrhage, biliary hemorrhage, retinal hemorrhage, nasal hemorrhage, oral hemorrhage, digestive hemorrhage, gastric hemorrhage, intestinal hemorrhage, rectal hemorrhage, puerperal hemorrhage, metrorrhagia, postoperative hemorrhage, traumatic hemorrhage, etc.; pain due to internal or external injury, cancer pain, headache, eye pain, ear pain, nasal pain, oral pain, skin pain, heart pain, liver pain, stomach pain, lung pain, visceral pain, limb pain; allergic rhinitis, asthma, eczema, urticaria, purpura, drug allergy, food allergy, ultraviolet allergy, allergic constitution, various allergies and anaphylactoid; mania, insomnia, anxiety, depression; fever, high fever of unknown cause, low fever; burn, scald, convulsion, epilepsy, hypertension, headache, nausea, emesis, edema, and apoplexy due to tumor chemotherapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810658397.1A CN110624011B (en) | 2018-06-22 | 2018-06-22 | Preparation and application of coke hawthorn carbon quantum dots (nano particles/nano particles) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810658397.1A CN110624011B (en) | 2018-06-22 | 2018-06-22 | Preparation and application of coke hawthorn carbon quantum dots (nano particles/nano particles) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110624011A true CN110624011A (en) | 2019-12-31 |
| CN110624011B CN110624011B (en) | 2022-03-18 |
Family
ID=68966723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810658397.1A Active CN110624011B (en) | 2018-06-22 | 2018-06-22 | Preparation and application of coke hawthorn carbon quantum dots (nano particles/nano particles) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110624011B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114314561A (en) * | 2022-01-13 | 2022-04-12 | 上海中医药大学 | Carbon dots with hawthorn as carbon source and preparation method thereof |
| CN115737759A (en) * | 2021-09-03 | 2023-03-07 | 北京中医药大学 | Charred triplet nano-particles for reducing blood fat |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105366659A (en) * | 2015-12-14 | 2016-03-02 | 上海交通大学 | Method for hydro-thermal synthesis of carbon quantum dots based on fruits |
-
2018
- 2018-06-22 CN CN201810658397.1A patent/CN110624011B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105366659A (en) * | 2015-12-14 | 2016-03-02 | 上海交通大学 | Method for hydro-thermal synthesis of carbon quantum dots based on fruits |
Non-Patent Citations (3)
| Title |
|---|
| MEILING ZHANG ET AL.: "Novel carbon dots derived from Schizonepetae Herba Carbonisata and investigation of their haemostatic efficacy", 《ARTIFICIAL CELLS,NANOMEDICINE, AND BIOTECHNOLOGY》 * |
| XIAOMAN LIU等: "Novel Phellodendri Cortex (HuangBo)-derived carbon dots and their hemostatic effect", 《NANOMEDICINE》 * |
| XIN YAN等: "Hemostatic bioactivity of novel Pollen Typhae Carbonisata‑derived carbon quantum dots", 《JOURNAL OF NANOBIOTECHNOLOGY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737759A (en) * | 2021-09-03 | 2023-03-07 | 北京中医药大学 | Charred triplet nano-particles for reducing blood fat |
| CN114314561A (en) * | 2022-01-13 | 2022-04-12 | 上海中医药大学 | Carbon dots with hawthorn as carbon source and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110624011B (en) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101912484B (en) | Chinese medicinal composition for treating hypertension, hyperlipidemia and hyperglycemia | |
| CN101095736B (en) | Chinese traditional medicine composition for treating acute and chronic pharyngitis, tonsillitis and method of making the same | |
| CN110623997A (en) | Preparation and application of scutellaria baicalensis carbon quantum dots (nano particles/nano particles) | |
| CN110624011B (en) | Preparation and application of coke hawthorn carbon quantum dots (nano particles/nano particles) | |
| CN107260963B (en) | Method for preparing medicine for treating hypertension by using dendrobium officinale and radish seed as main materials | |
| CN104189588A (en) | Vitamin C Yinqiao tablets and preparation method thereof | |
| CN100588415C (en) | Capsule for treating chronic bronchitis and its preparing method | |
| CN101428117A (en) | Medicament for invigorating pulse and reducing adipose, and preparation method thereof | |
| CN105770462A (en) | Healthcare tea with blood lipid reducing function | |
| CN110628424A (en) | Preparation and application of malt carbon quantum dots (nano particles/nano particles) | |
| CN105362407A (en) | Composition for preventing and/or treating sub-health caused by smoking | |
| CN110628426A (en) | Preparation and application of rush carbon quantum dots (nano particles/nano particles) | |
| CN101874841A (en) | Total glycosides extractive of morinda plants, as well as preparation method and application thereof | |
| CN106943464A (en) | A kind of biological nutrition compound composition of adjusting hypertension | |
| CN115919977A (en) | Chinese medicinal formula for treating new coronavirus infection pathopoiesia and preparation method thereof | |
| CN104069144A (en) | Three formula granules for forming Shengmai powder and preparation method thereof | |
| CN103961441A (en) | Traditional Chinese medicine compound preparation, preparation method and medicine box thereof | |
| CN1259945C (en) | Antipyretic Chinese medicine preparation for child made of bupleurum root and cinnamon twig | |
| CN110623996A (en) | Preparation and application of schizonepeta spike carbon quantum dots (nanoparticles/nanoparticles) | |
| CN100417410C (en) | Medicine for treating gastrointestinal summer damp cold and preparing method thereof | |
| CN110623990A (en) | Preparation and application of Cirsium setosum carbon quantum dots (nanoparticles/nanoparticles) | |
| CN111991517A (en) | Traditional Chinese medicine capsule for qi and yin deficiency type diabetes and preparation method thereof | |
| CN101040905B (en) | Medicine made by selfheal for reducing blood sugar | |
| CN108740208A (en) | A kind of health-care bagged tea and preparation method thereof of energy lower hyperlipidemia, hypertension, hyperglycemia | |
| CN106994142A (en) | A kind of loquat extract and its hypoglycemic loquat black tea extract buccal tablet of preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |